Invizius inks Series A
Invizius Limited, a developer of treatments to suppress unwanted innate immune responses, has secured 5.3 million pounds in Series A financing.
Invizius Limited, a developer of treatments to suppress unwanted innate immune responses, has secured 5.3 million pounds in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination